{"prompt": "['MC1575', '20', 'Amendment 2', '5.0', 'STRATIFICATION FACTORS: None', '6.0', 'REGISTRATION PROCEDURES', '6.1', 'Registration', '6.11', 'Mayo Clinic Sites', 'To register a patient, access the Mayo Clinic Cancer Center (MCCC)', 'web page and enter the remote registration/randomization application.', 'The registration/randomization application is available 24 hours a day, 7', 'days a week. Back up and/or system support contact information is', 'available on the Web site. If unable to access the Web site, call the', 'MCCC Registration Office at', 'between the hours of 8', 'a.m. and 5:00 p.m. Central Time (Monday through Friday).', 'The instructions for the registration/randomizatior application are available on', 'the MCCC web page', 'and detail the', 'process for completing and confirming patient registration. Prior to initiation of', 'protocol treatment, this process must be completed in its entirety and a MCCC', 'subject ID number must be available as noted in the instructions. It is the', 'responsibility of the individual and institution registering the patient to confirm', 'the process has been successfully completed prior to release of the study agent.', 'Patient registration via the registration/randomizatior application can be', 'confirmed in any of the following ways:', 'Contact the MCCC Registration Office', 'If the patient was', 'fully registered, the MCCC Registration Office staff can access the', 'information from the centralized database and confirm the registration.', 'Refer to \"Instructions for Remote Registration\" in section', '\"Finding/Displaying Information about A Registered Subject.\"', '6.12', 'Non-Mayo Clinic sites', 'To register a patient, fax', 'a completed eligibility checklist to the', 'Mayo Clinic Cancer Center (MCCC) Registration Office between 8 a.m. and', '4:30 p.m. central time Monday through Friday.', '6.2', 'Verification', 'Prior to accepting the registration, registration/randomization application will verify the', 'following:', 'IRB approval of the study', 'Patient eligibility', 'Existence of a signed consent form', 'Existence of a signed authorization for use and disclosure of protected health', 'information', 'Protocol Version Date: :16Aug2018']['MC1575', '21', 'Amendment 2', '6.3', 'Documentation of IRB approval', 'Documentation of IRB approval must be on file in the Registration Office before an', 'investigator may register any patients.', 'In addition to submitting initial IRB approval documents, ongoing IRB approval', 'documentation must be on file (no less than annually) at the Registration Office (fax:', 'If the necessary documentation is not submitted in advance of attempting', 'patient registration, the registration will not be accepted and the patient may not be', 'enrolled in the protocol until the situation is resolved.', 'When the study has been permanently closed to patient enrollment, submission of annual', 'IRB approvals to the Registration Office is no longer necessary.', '6.4', 'Correlative studies', 'An optional correlative component is part of this study. There will be an option to select', 'if the patient is to be registered onto this component (see Section17.2).', 'Patient has/has not given permission to use his/her tissue sample for research testing', 'At the time of registration, the following will be recorded:', 'Patient has/has not given permission to store and use his/her sample(s) for future', 'research of cancer at Mayo.', 'Patient has/has not given permission to store and use his/her sample(s) for future', 'research to learn, prevent, or treat other health problems.', 'Patient has/has not given permission for MCCC to give his/her sample(s) to', 'researchers at other institutions.', '6.5', 'Treatment on protocol', 'Treatment on this protocol must commence at enrolling institution under the supervision', 'of a medical oncologist or endocrinologist', '6.6', 'Treatment start', 'Treatment cannot begin prior to registration and must begin <14 days after registration.', '6.7', 'Pretreatment', 'Pretreatment tests/procedures (see Section 4.0) must be completed within the guidelines', 'specified on the test schedule.', '6.8', 'Baseline symptoms', 'All required baseline symptoms (see Section 10.0) must be documented and graded.', '6.9a', 'Study drug availability', 'Study drug is available on site for this patient.', '6.9b', 'Booklet availability', 'Patient questionnaire booklet is available on site for this patient; copies are not acceptable', 'for this submission.', '6.9c', 'Consultation with hypertension specialist', 'A hypertension specialist (endocrinologist, or cardiologist, or nephrologist) at enrolling', 'institution has seen this patient and confirms the patient is a suitable candidate for this', 'study <14 days prior to registration.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}